REG - Oxford Biomedica PLC - Oxford Biomedica Solutions forms new partnerships

Oxford BioMedicaAnnouncement

14/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221214:nRSN6070Ja&default-theme=true

RNS Number : 6070J  Oxford Biomedica PLC  14 December 2022

 

Oxford Biomedica Solutions forms new partnerships with three biotechnology
companies

-       Agreements signed with three new partners, bringing the total
number of new AAV customers in 2022 to four, ahead of original target

 

Oxford, UK - 14 December 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces that its subsidiary Oxford Biomedica Solutions LLC ("Oxford
Biomedica Solutions"), a high-performing full-scope AAV manufacturing and
innovation business, has signed agreements with three new, undisclosed, U.S.
based biotechnology companies. This is in addition to the new AAV customer
announced in September 2022. Oxford Biomedica Solutions has now secured four
new AAV customers, ahead of the previously stated target of two by the end of
the calendar year.

Under these additional agreements, Oxford Biomedica Solutions will provide its
full platform offering to support the new partners' pre-clinical gene therapy
programmes, which cover development programmes in indications including CNS,
autoimmune disease, oncology, muscular disorder, and rare metabolic disease.
Oxford Biomedica Solutions' end-to-end capabilities range from construct
design to process development to IND support and GMP manufacturing, including
a proven platform that has demonstrated high quality titres of E15 vg/L and
achieved over 90% fully intact vector.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented:
"Securing four new AAV customers in 2022 exceeds our original stated target of
two new customers by the end of 2022. We are making considerable progress
towards becoming a global viral vector leader across all key vector types,
with this momentum in Oxford Biomedica Solutions adding to the strength and
depth of our UK-based operations. AAV is a significant, high growth market,
and the cadence of new business wins further reinforces our confidence in the
potential of our AAV platform, which has already demonstrated high titre
product quality and a full breadth of capabilities. We enter 2023 with great
confidence and look forward to continuing to build our position as a
world-class, innovation-led CDMO delivering life-changing and life-altering
therapies to patients."

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 919 539 1234 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Cole            / Angela Gray

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
U.S. based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) and
www.oxbsolutions.com (http://www.oxbsolutions.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPADFDFAFFA